sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Ticagrelor

Medicine · P2Y12 Platelet Inhibitor

Ticagrelor

Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).

Medication guideLabel updated 2026-05-30

Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗

Boxed warning

WARNING: BLEEDING RISK • Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal bleeding. • Do not use ticagrelor tablets in patients with active pathological bleeding or a history of intracranial hemorrhage. •Do not start ticagrelor tablets in patients undergoing urgent coronary artery bypass graft surgery (CABG). • If possible, manage bleeding without discontinuing ticagrelor tablets. Stopping ticagrelor tablets increases the risk of subsequent cardiovascular events. WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. • Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.

Drug facts

Used for
  • For at least the first 12 months following ACS, it is superior to clopidogrel.
  • Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.
  • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events.
How to take it
Take ticagrelor tablets exactly as prescribed by your healthcare provider.

What it is used for

Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.

to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).

1.1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel.

Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events.

While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) Ticagrelor tablets are indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).

The most important thing to know

Ticagrelor tablets are used to lower your chance of having, or dying from, a heart attack or stroke. Ticagrelor tablets (and similar drugs) can cause bleeding that can be serious and sometimes lead to death. In cases of serious bleeding, such as internal bleeding, the bleeding may result in the need for blood transfusions or surgery.

While you take ticagrelor tablets: you may bruise and bleed more easily you are more likely to have nose bleeds it will take longer than usual for any bleeding to stop Call your healthcare provider right away, if you have any of these signs or symptoms of bleeding while taking ticagrelor tablets: bleeding that is severe or that you cannot control pink, red or brown urine vomiting blood or your vomit looks like “coffee grounds” red or black stools (looks like tar) coughing up blood or blood clots D o not stop taking ticagrelor tablets without talking to the healthcare provider who prescribes it for you.

People who are treated with a stent, and stop taking ticagrelor tablets too soon, have a higher risk of getting a blood clot in the stent, having a heart attack, or dying. If you stop ticagrelor tablets because of bleeding, or for other reasons, your risk of a heart attack or stroke may increase. Your healthcare provider may instruct you to stop taking ticagrelor tablets 5 days before surgery.

This will help to decrease your risk of bleeding with your surgery or procedure. Your healthcare provider should tell you when to start taking ticagrelor tablets again, as soon as possible after surgery. Taking ticagrelor tablets with aspirin Ticagrelor tablets are taken with aspirin unless your healthcare provider specifically tells you otherwise.

Talk to your healthcare provider about the dose of aspirin that you should take with ticagrelor tablets. In most cases, you should not take a dose of aspirin higher than 100 mg daily.

How to take it

Take ticagrelor tablets exactly as prescribed by your healthcare provider. Your healthcare provider will tell you how many ticagrelor tablets to take and when to take them. Take ticagrelor tablets with aspirin, unless your healthcare provider specifically tells you otherwise. You may take ticagrelor tablets with or without food.

Take ticagrelor tablets two times each day, around the same times each day. If you miss your scheduled dose of ticagrelor tablets, take your next dose at its scheduled time. Do not take 2 doses at the same time unless your healthcare provider tells you to. If you take too much ticagrelor tablets, call your healthcare provider or local poison control center or go to the nearest emergency room right away.

If you are unable to swallow the tablet(s) whole, you may crush the ticagrelor tablet(s) and mix it with water. Drink all the water right away. Refill the glass with water, stir, and drink all the water. Ticagrelor tablets may also be given through certain nasogastric (NG) tubes. Ask your healthcare provider for instructions on how to take ticagrelor tablets through a NG tube

Side effects, and when to stop

Ticagrelor tablets can cause serious side effects, including: S hortness of breath. Tell your healthcare provider if you have new, worsening or unexpected shortness of breath when you are at rest, at night, or when you are doing any activity. Slow or irregular heartbeat. Irregular breathing. Tell your healthcare provider if you develop irregular breathing patterns when asleep or awake such as speeding up, slowing down or short pauses in breathing.

Your healthcare provider will decide if you need further evaluation. These are not all of the possible side effects of ticagrelor tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Who should not take it

Do not take doses of aspirin higher than what your healthcare provider tells you to take. Tell your healthcare provider if you take other medicines that contain aspirin, and do not take new over-the-counter medicines with aspirin in them. What are ticagrelor tablets? Ticagrelor tablets are a prescription medicine used to: decrease your risk of death, heart attack, and stroke in people with a blockage of blood flow to the heart (acute coronary syndrome or ACS) or a history of a heart attack.

Ticagrelor can also decrease your risk of blood clots in your stent in people who have received stents for the treatment of ACS. decrease your risk of a first heart attack or stroke in people who have a condition where the blood flow to the heart is decreased (coronary artery disease or CAD) who are at high risk for having a heart attack or stroke.

decrease your risk of stroke in people who are having a stroke (acute ischemic stroke) or mini-stroke (transient ischemic attack or TIA). It is not known if ticagrelor tablets are safe and effective in children. Do not take ticagrelor tablets if you: have a history of bleeding in the brain are bleeding now are allergic to ticagrelor or any of the ingredients in ticagrelor tablets.

See the end of this Medication Guide for a complete list of ingredients in ticagrelor tablets. Before taking ticagrelor tablets, tell your healthcare provider about all of your medical conditions, if you: have had bleeding problems in the past have had any recent serious injury or surgery plan to have surgery or a dental procedure.

have a history of stomach ulcers or colon polyps have lung or breathing problems, such as COPD or asthma have liver problemshave have a history of stroke are pregnant or plan to become pregnant. It is not known if ticagrelor tablets will harm your unborn baby. You and your healthcare provider should decide if you will take ticagrelor tablets.

are breastfeeding or plan to breastfeed. It is not known if ticagrelor passes into your breast milk. You should not breastfeed during treatment with ticagrelor tablets. Talk to your healthcare provider about the best way to feed your baby during treatment with ticagrelor tablets. Tell all of your healthcare providers and dentists that you are taking ticagrelor tablets.

They should talk to the healthcare provider who prescribed ticagrelor tablets for you before you have any surgery or procedure. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Ticagrelor tablets may affect the way other medicines work, and other medicines may affect how ticagrelor tablets work.Certain medicines may increase your risk of bleeding.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Storing it

Store ticagrelor tablets at room temperature between 20ºC to 25°C (68ºF to 77°F). Keep ticagrelor tablets and all medicines out of the reach of children.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Ticagrelor; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/ticagrelor

APA 7th

sofidex. (2026, August 2). Ticagrelor. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/ticagrelor

AMA 11th

Ticagrelor. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/ticagrelor

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.